Possible explaination for Finasteride Reflex Hyperandrogenicity
    4/20/2022

    From the encyclopedia
    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    Minoxidil →

    Vasodilator used on the scalp and, at low doses, as a tablet

    Microneedling →

    Technique that makes tiny punctures in the scalp with fine needles

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💊 Finasteride (oral) 1mg every other day 1 year
    💧 Minoxidil (topical)
    💧 Dermarolling (topical) 1.5mm every few weeks
    the tone is 😞 negative with no growth results.

    Other terms

    The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

      community Androgenetic alopecia is a skin disease: DHT-mediated skin disorders

       63 upvotes 2 years ago
      Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

      community Female 37/F - On Meds, but no progress. Add PRP?

       4 upvotes 3 years ago
      A 37-year-old woman with androgenetic alopecia is using spironolactone, oral and topical minoxidil, and considering PRP therapy due to lack of progress. She is unable to obtain finasteride, dutasteride, or bicalutamide and is exploring other options like Clascoterone and RU58841.

      community Chat is this real? Compound called clascoterone

       581 upvotes 9 months ago
      Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

    Related Research

    6 / 6 results